Organic Chemistry Methods TRIZ Cases

A water-propanol crystallization process produces stable Ozanimod hydrochloride Form A, reducing charging and adhesion during production.

A streamlined metal-complex route targets over 99% enantiomeric excess while avoiding costly resolution and reducing waste.

Nitrile, ester, and alcohol-based crystallization yields FGFR inhibitor forms A and B for manufacturing, storage, and use.

An emitting-auxiliary layer bridges energy levels, improving color purity while limiting Joule-heating damage in organic elements.

This case examines polymorphs, hydrates, and solvates that stabilize ABCA1 expression and activity for kidney disease therapy.

This case develops Formula I PPARG inverse agonists to inhibit PPARG activity and expand therapeutic options for urothelial cancer.

A water-based heating and cooling process forms crystalline Lorlatinib:Fumaric acid for improved solubility, stability, and handling.

Ethanol, acetone, or isopropanol extraction concentrates marigold lutein ester for high-purity crystals with fewer steps.

Green solvents streamline N-substituted cyclic peptide synthesis and crystallization.

Deuterated emitting compounds improve OLED stability and extend device lifetime.

Controlled crystallization of brequinar sodium form C improves crystal consistency for stable oral dosage manufacturing and storage.

This case uses a benzisoxazole sulfonamide core and tailored substituents to inhibit MYST KATs and suppress abnormal cell growth.

Amine compounds address heat resistance by combining hole transport and electron blocking for efficient, longer-lived organic EL devices.

Novel linked compounds target KRAS G12C, G12D, and other mutants while balancing inhibitory activity, pharmacokinetics, and safety.

This case uses a crystalline five-membered N-heterocycle to inhibit HBV capsid assembly while improving compound stability.

Form-C2 through Form-C5 use solvent- and temperature-controlled crystallization to improve Acalabrutinib solubility and stability.

Chelator-mediated radiolabelling preserves MGL binding while enabling PET measurement of expression, distribution, and enzyme occupancy.

This case uses polypharmacophore compounds to inhibit kinase and demethylase networks, extending efficacy while improving specificity.

A sub-39° molecular angle in the emission-layer compound improves low-grayscale luminescence and display quality.

This process replaces microwave heating and HPLC purification with conventional heating and ethyl acetate recrystallization for 98%+ purity.

Pre-formed [Al18F] complexes support efficient labeling of heat-sensitive biomolecules at ambient temperature with improved serum stability.

Composite OLED host materials target lower voltage, higher efficiency, and longer lifespan.

Defined crystalline forms block HBV capsid assembly and address stability constraints while targeting the persistent cccDNA reservoir.

This case uses amorphous calcium salt forms and controlled precipitation to improve stability, yield, and industrial scalability.

This case uses modular compound synthesis to develop aromatase inhibitors and estrogen-receptor-active agents for therapy-resistant cancers.

Direct one-phase crystallization limits residual solvents and mixed forms, improving Ixazomib Citrate purity and solid-state stability.

A three-compound light-emitting layer uses carbon-carbon bonds and energy-level alignment to inhibit decomposition and preserve luminance.

This case combines two defined host compounds in the emitting layer to improve efficiency, driving voltage, and device lifespan.

A composite host pairs electron- and hole-transport compounds to improve efficiency, reduce roll-off, and extend blue-emission lifespan.

Spirobifluorene and triarylamine structures balance glass transition temperature, conductivity, lifetime, and operating voltage in OLEDs.

A composite host with phosphorescent and fluorescent emitters balances excitons and charge flow to improve efficiency and lifespan.

This OLED case combines p-type and n-type hosts in blue layers, using exciplex and delayed fluorescence to improve efficiency and lifespan.

A bipolar host-guest composition balances electron and hole mobility, supports exciton transfer to blue dopants, and limits roll-off.

Cationic PEG solid supports reversibly adsorb DNA-conjugated molecules for organic-solvent reactions without water.

A carbazole and triphenylene mixed host balances electron and hole mobility, improving blue OLED efficiency and lifespan.

This case uses controlled crystallization and purification to produce stable, high-purity Voclosporin forms with improved bioavailability.

A two-compound OLED composition balances electron and hole mobility, guiding exciton transfer for better efficiency and lifespan.

This case combines crystallization with HPLC and HILIC to produce pharmaceutical-grade migalastat hydrochloride with impurities below 0.5%.

Coformers such as vanillin and amino acids form CBDA cocrystals that preserve purity, shelf life, solubility, and bioavailability.

Controlled FDCA dissolution in an organic acid solvent reduces FCA and FDCA-Me impurities and improves particle handling.

Controlled Mo-V-Sb-Nb-W oxide composition improves acrylonitrile yield during propane or isobutane ammoxidation.

Enzymatic resolution with in-situ racemization addresses the 50% yield limit while producing enantioenriched BTK intermediates.

Controlled IRAK4 salt crystallization uses X-ray-defined forms to improve solubility, pharmacokinetics, and stability.

Combining Ketoprofen, Lysine, and Gabapentin in a co-crystal improves solubility and supports faster, broader pain relief.

This OLED case uses Pt/Pd tetradentate compounds to improve saturated deep blue and red emission without complex device layers.

This case combines dye-based proton stabilization with imidazoline chemistry to improve corrosion inhibition, solubility, and detection.

This case uses a Formula 1 heterocyclic compound in device interlayers to enhance luminance, driving voltage, response speed, and stability.

Specific aromatic substituents in OLED compounds support electron-hole transport, recombination, light emission, and stability.

Crystalline forms, salts, and co-crystals address HIV drug stability and manufacturing challenges while supporting bioavailability.

This OLED case uses a condensed cyclic compound interlayer to improve efficiency, voltage, lifespan, and narrow blue emission.